ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1916

Defining Early-stage Knee Osteoarthritis: A Scoping Review
Abstract Number: 1917

A Remote Behaviorally-Designed Intervention to Promote Physical Activity in Patients with Knee Osteoarthritis: Results of a Pilot Randomized Clinical Trial
Abstract Number: 1918

Neurobiological Mechanisms of a Remote-Delivered Mind-body Intervention for Knee Osteoarthritis
Abstract Number: 1919

Underdiagnosis and Undertreatment of Knee Osteoarthritis in Persons with Type 2 Diabetes: A Cross-sectional Study
Abstract Number: 1920

Gait and Physical Activity Predictors of Knee Replacement: A Machine Learning Analysis in the Multicenter Osteoarthritis Study
Abstract Number: 1921

Association Between Knee Osteoarthritis and Health-Related Quality of Life in Persons with Type 2 Diabetes
Abstract Number: 1922

Multi-Joint Osteoarthritis Phenotypes by Race/Ethnicity and Sex: Preliminary Descriptive Data from the Johnston County Health Study
Abstract Number: 1923

Co-fluctuations of Knee Pain Between Knees in the Same Person: Data from the Osteoarthritis Initiative (OAI)
Abstract Number: 1924

Reading the Waves: Identifying Distinct Phenotypes of Multisystem Inflammatory Syndrome in Children During the 2020-2021 COVID-19 Pandemic
Abstract Number: 1925

Characterizing Phenotypic Changes by SARS-CoV-2 Variant in Multisystem Inflammatory Syndrome in Children (MIS-C): A Single Institution Case Series
Abstract Number: 1926

Analysis of New Patient Referrals to a Large Pediatric Rheumatology Clinic
Abstract Number: 1927

Patient and Parent Perceptions of an Established Rheumatology Transition Clinic for Adolescents and Young Adults
Abstract Number: 1928

Idiopathic Pulmonary Capillaritis Within the Spectrum of Pediatric Diffuse Alveolar Hemorrhage
Abstract Number: 1929

Outcomes and Safety of Anakinra for the Treatment of Multisystem Inflammatory Syndrome in Children
Abstract Number: 1930

Assessing the Number of Children Evaluated for Recurrent Fevers During the COVID-19 Pandemic in North America

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].